Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer

J Gynecol Oncol. 2024 Jan 25. doi: 10.3802/jgo.2024.35.e66. Online ahead of print.ABSTRACTIn the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.PMID:38330382 | DOI:10.3802/jgo.2024.35.e66
Source: Journal of Gynecologic Oncology - Category: OBGYN Authors: Source Type: research